Welcome to our dedicated page for Repligen SEC filings (Ticker: RGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Scaling biologics isn鈥檛 simple鈥攏either are Repligen鈥檚 SEC documents. Revenue from chromatography columns, hollow-fiber filters, and process analytics is scattered across hundreds of pages, and insider moves can signal shifting demand from top CDMOs. If you have ever searched 鈥淩epligen insider trading Form 4 transactions鈥� or wondered how to extract segment sales from the latest 10-K, you know the challenge.
Stock Titan solves the puzzle. Our AI reads every filing the instant it posts to EDGAR, then delivers plain-English answers to questions like 鈥淩epligen quarterly earnings report 10-Q filing highlights鈥� or 鈥淩epligen 8-K material events explained.鈥� Instead of wading through accounting footnotes, you receive:
- AI-powered summaries that translate complex bioprocess jargon
- AG真人官方-time alerts for Repligen Form 4 insider transactions real-time
- Direct links to the full documents, plus key metrics already extracted
Whether you鈥檙e tracking Repligen annual report 10-K simplified for chromatography backlog, comparing margin trends across quarters, or monitoring Repligen executive stock transactions Form 4 ahead of earnings, our platform keeps you current. You鈥檒l also find proxy statement detail鈥斺�淩epligen proxy statement executive compensation鈥� questions answered鈥攁nd quick takes on every 8-K announcement. In short, understanding Repligen SEC documents with AI means spending minutes, not days, to surface what drives valuation.
Use the time saved to focus on strategy while we handle the filings鈥攂ecause Repligen earnings report filing analysis should be insight, not busywork.
Martin D. Madaus, a director of Repligen Corporation (RGEN), reported an insider purchase of 1,800 shares of common stock on 08/08/2025 at a weighted-average price of $112.128 per share. The filing shows those 1,800 shares are beneficially owned and held indirectly through the Martin D. Madaus 2011 Revocable Trust. The Form 4 also lists a disposition of 5,586 shares and indicates 11 shares held indirectly in a spouse trust. The report identifies the filer as a director and provides the weighted-average purchase price and the trustee holdings without additional context on total holdings or prior positions.
FAQ
What is the current stock price of Repligen (RGEN)?
What is the market cap of Repligen (RGEN)?
